Imagine your body has old, dormant viral blueprints hidden in its DNA that only wake up and appear when a cell becomes cancerous. This project creates a vaccine that teaches your immune system to recognize these specific 'viral' markers. Once the immune system sees these markers, it can hunt down and destroy cancer cells while leaving healthy cells alone.
Many cancers are resistant to current immunotherapies because they lack targetable antigens. This creates a massive unmet need for treatments that can target 'undruggable' markers across various solid tumor types.
A first-in-class vaccine candidate (IPT001) and a scalable, GMP-compatible manufacturing process for Ad19 and Ad5F35 viral vectors.
If you are a drug developer dealing with cancers that don't respond to current immunotherapies — this project developed IPT001 that targets HERVs present in up to 90% of prostate and ovarian cancers to trigger a strong T-cell response.
If you are a CRO dealing with the need for new first-in-human trial candidates — this project developed a GMP-compatible manufacturing process for Ad19 and Ad5F35 vectors to enable clinical evaluation.
If you are a clinic dealing with patients with pancreatic cancer (80% HERV expression) — this project developed a vaccine platform that can be used in combination with checkpoint inhibitors to improve patient outcomes.
Based on available project data, specific pricing or cost per dose is not disclosed.
Yes, the project focused on developing scalable, GMP-compatible manufacturing processes for the Ad19 and Ad5F35 vaccine vectors.
Based on available project data, the technology is developed by INPROTHER APS, but specific licensing terms are not mentioned.
The project included engagement with regulatory authorities to prepare for clinical trial applications and first-in-human evaluation.
The project period runs from 2022-07-01 to 2025-10-31, focusing on the transition to first-in-human trials.
The project is led by a single SME, INPROTHER APS from Denmark, which holds a 100% industry ratio. This lean structure suggests a highly focused commercial drive, as the company is directly managing the transition from preclinical data to GMP manufacturing and regulatory filing.
Contact INPROTHER APS in Denmark for licensing and clinical partnership inquiries.
Contact us to explore partnership opportunities with HERV-targeted immunotherapy developers.
